VNDA Share Price

Open 13.90 Change Price %
High 14.15 1 Day 0.25 1.81
Low 13.75 1 Week -0.20 -1.40
Close 14.05 1 Month -1.20 -7.87
Volume 304760 1 Year 4.56 48.05
52 Week High 18.00
52 Week Low 9.85
VNDA Important Levels
Resistance 2 14.42
Resistance 1 14.27
Pivot 13.98
Support 1 13.83
Support 2 13.68
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
DCTH 0.02 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
CMCSA 40.34 0.02%
More..
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
CPSL 0.09 50.00%
LOCM 0.09 50.00%
BCRX 6.73 31.19%
WRES 0.09 28.57%
CGEI 0.28 27.27%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
LIME 2.15 22.16%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA)

VNDA Technical Analysis 3
As on 25th May 2017 VNDA Share Price closed @ 14.05 and we RECOMMEND Sell for LONG-TERM with Stoploss of 14.45 & Sell for SHORT-TERM with Stoploss of 14.34 we also expect STOCK to react on Following IMPORTANT LEVELS.
VNDA Target for May
1st Target up-side 16.49
2nd Target up-side 17.36
3rd Target up-side 18.23
1st Target down-side 14.01
2nd Target down-side 13.14
3rd Target down-side 12.27
VNDA Other Details
Segment EQ
Market Capital 96253192.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.vandapharmaceuticals.com
VNDA Address
VNDA
2200 Pennsylvania Avenue NW
Suite 300E
Washington, DC 20037
United States
Phone: 202-734-3400
Fax: 202-296-1450
VNDA Latest News
Interactive Technical Analysis Chart Vanda Pharmaceuticals Inc. ( VNDA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Vanda Pharmaceuticals Inc.
VNDA Business Profile
Vanda Pharmaceuticals Inc. (Vanda) is a biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of central nervous system disorders. The Company�s product portfolio includes tasimelteon, a compound for the treatment of circadian rhythm sleep disorders (CRSD), which is in clinical development for Non-24, Fanapt, a compound for the treatment of schizophrenia, the oral formulation of which is being marketed and sold in the United States by Novartis Pharma AG (Novartis), and VLY-686, a small molecule neurokinin-1 receptor (NK-1R) antagonist.